Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  CVS Health    CVS

Mes dernières consult.
Most popular
News SummaryMost relevantAll newsSector newsTweets

CVS: Protecting Consumers in an Environment of Rising Drug Prices

share with twitter share with LinkedIn share with facebook
share via e-mail
06/13/2017 | 12:15pm CEST

Release date- 12062017 - CVS: Protecting Consumers in an Environment of Rising Drug Prices.

Rising drug prices is one of today's most discussed health care topics, and with good reason: double-digit price hikes for brand name drugs are becoming more commonplace and can jeopardize access to medications and put financial strain on patients and taxpayers. In fact, brand price inflation was a key driver of total drug spending in 2016, which reached a record high of $450 billion.1

Pharmacy benefit managers (PBMs) provide a check on rising drug prices by using competition to negotiate discounts and promote the appropriate use of lower-cost, clinically equivalent medicines. In 2016, the rate of drug spending, also known as trend, dropped to an average of 3.2 percent for CVS Caremark clients, in contrast to a trend of 11 percent without PBM strategies in place.

Consumers Benefit from PBM Strategies

The majority of consumers with prescription drug coverage has relatively low out-of-pocket costs. Nearly 60 percent of those covered by CVS Health-administered plans spent less than $100 in out-of-pocket costs in 2016, a slight decline from the prior year.

PBMs have several strategies for helping patients keep their out-of-pocket and premium costs low, including:

Identifying when lower cost, clinically equivalent medicines can be used instead of high-cost brand name drugs. In fact, nine out of ten prescriptions dispensed in 2016 were generic drugs.2

Using industry expertise to negotiate discounts with manufacturers, which are passed on to plan sponsors according to contract terms and can be used to lower premiums or reduce cost-sharing for consumers.

Developing innovative prescription savings programs, such as Reduced Rx, which offer discounts directly to patients on certain essential medications.

The Rise in High-Deductible Health Plans

In 2016, 29 percent of workers in employer-sponsored plans were covered by a high deductible health plan (HDHP) - that's five times more than 10 years before.3 For many consumers, enrolling in an HDHP represents their first exposure to drug list prices during the deductible phase of coverage. Though only four percent of individuals covered by a CVS Health-administered plan spent more than $1,000 annually on prescription drugs, we find that many members with high out-of-pocket costs are also in HDHPs.

Point-of-Sale Discounts Can Reduce Patient Out-of-Pocket Costs

We understand the challenges some consumers face with rising drug costs, which is one reason we developed the capability for clients to apply negotiated discounts at the point-of-sale, thus reducing a member's out-of-pocket cost for a prescription. Research shows that out-of-pocket costs may be a barrier to accessing needed medical care, so a solution like point-of-sale discounts can potentially help improve medication adherence. Several CVS Caremark clients have implemented this solution, and we are using it for our own employee benefit as well.

Providing Flexibility to Expand Drug Coverage for Consumers with Health Savings Accounts

Health savings accounts are available to individuals enrolled in HDHPs and may be used to pay for qualified medical expenses, including prescription medications. Under current law, certain drugs that are considered preventive can be covered at the same copay as if the deductible has been met, and in some cases at no cost to the patient. However, medications used to treat an existing disease, injury or condition may not be covered, meaning the individual has to pay the full cost until the deductible is reached.

CVS Health advocates for policy changes that would allow more flexibility for HDHPs to cover prescription drugs, beyond those that qualify for the preventive drug list, prior to reaching the deductible. These changes have the potential to make medicines more accessible, encourage patients to take their medications as prescribed and keep health care costs low.

For more information on how CVS Health is working to ensure consumers have access to affordable medicines, visit our Rising Drug Prices information center. And to stay informed about the most talked-about topics in health care, register for content alerts and our bi-weekly health care newsletter.

(c) 2017 Electronic News Publishing -, source ENP Newswire

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on CVS HEALTH
10/20 CVS HEALTH : Dividend Coverage: This Pharmacy Company has a Dividend Yield of 2...
10/19 CVS HEALTH : SilverScript Insurance Company, a CVS Health Company, Introduces Ne..
10/19 EXPRESS SCRIPTS : Anthem will turn to CVS for prescriptions
10/19 EXPRESS SCRIPTS : Anthem to turn to CVS after troubled deal
10/19DJAnthem To Launch Pharmacy Benefit Manager -- WSJ
10/18DJAnthem to Launch Its Own Pharmacy-Benefit Manager--3rd Update
10/18DJAnthem to Launch Its Own Pharmacy-Benefit Manager--2nd Update
10/18 MARKETS RIGHT NOW : US stocks closing higher; IBM surges
10/18 Anthem will turn to CVS after troubled Express Scripts deal
10/18DJAnthem to Launch Its Own Pharmacy-Benefit Manager--2nd Update
More news
News from SeekingAlpha
10/19 Dividend Growth Stocks Going Ex-Div October 23th-27th
10/19 Stocks Going Ex-Dividend The Fourth Week Of October
10/18 PHARMACY BEARS : High On Drugs
10/18 CVS Health inks five-year deal with Anthem to support PBM unit; shares up 2% ..
10/17 A REAL DIVIDEND GROWTH MACHINE : Q3 2017 Portfolio Review
Financials ($)
Sales 2017 184 B
EBIT 2017 10 051 M
Net income 2017 5 266 M
Debt 2017 24 750 M
Yield 2017 2,61%
P/E ratio 2017 14,75
P/E ratio 2018 12,82
EV / Sales 2017 0,55x
EV / Sales 2018 0,52x
Capitalization 75 866 M
Duration : Period :
CVS Health Technical Analysis Chart | CVS | US1266501006 | 4-Traders
Technical analysis trends CVS HEALTH
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 24
Average target price 86,7 $
Spread / Average Target 16%
EPS Revisions
Larry J. Merlo President, CEO & Non-Independent Director
David Wyatt Dorman Non-Executive Chairman
Jonathan C. Roberts Chief Operating Officer & Executive Vice President
David M. Denton Chief Financial Officer & Executive Vice President
Troyen A. Brennan Chief Medical Officer & Executive Vice President
Sector and Competitors
1st jan.Capitalization (M$)
CVS HEALTH-5.42%75 327